Public company research profile

This public-disclosure research profile is not investment advice. It summarizes historical public filings, source links, confidence context, and hypothetical outcomes so readers can verify the evidence themselves.

Open in CopyWindow

Company research history

er Edwards Lifesciences Corporation Common Stock (EW)

Source-transparent disclosure history for this company, built from public CopyWindow signals and previous hypothetical outcomes.

13 disclosures
8 insiders
0 cluster signals
0.0% avg. 30d outcome

Company facts

Ticker / ISIN
EW / Not available
Exchange
Not available
Country
US
Sector
Not available

Disclosure history

Josh Gottheimer, Representative

sell disclosed on 29 Dec 2025 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Jefferson Shreve, Representative

sell disclosed on 22 Jun 2025 via House STOCK Act disclosures

Transaction value
Not available
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Bruce Westerman, Representative

sell disclosed on 12 May 2025 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Jefferson Shreve, Representative

buy disclosed on 8 May 2025 via House STOCK Act disclosures

Transaction value
Not available
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Rob Bresnahan, Representative

buy disclosed on 8 May 2025 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Bruce Westerman, Representative

buy disclosed on 16 Apr 2025 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Mike Kelly, Representative

sell disclosed on 14 Jun 2024 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Josh Gottheimer, Representative

buy disclosed on 7 Jan 2024 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

John Curtis, Representative

sell disclosed on 15 Dec 2023 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

John Curtis, Representative

buy disclosed on 7 Aug 2023 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Zoe Lofgren, Representative

sell disclosed on 6 Jun 2023 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

John Curtis, Representative

buy disclosed on 10 May 2023 via House STOCK Act disclosures

Transaction value
1.001 US$
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%

Daniel Goldman, Representative

buy disclosed on 17 Apr 2023 via House STOCK Act disclosures

Transaction value
Not available
Copy Window
Probably too late
Data Confidence
93%
Previous signal outcome
0.0%